ABOS
$2.67-0.25 (-8.56%)
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinan...
Recent News
Acumen Pharmaceuticals Spotlights Sabirnetug Phase II Progress, JCR Brain-Delivery Partnership at Conference
Acumen Pharmaceuticals (NASDAQ:ABOS) executives outlined key clinical and research milestones for the company’s Alzheimer’s disease pipeline during a discussion focused on its lead antibody, sabirnetug, and an enhanced brain delivery (EBD) collaboration with Japan-based JCR Pharmaceuticals. Company
Acumen Pharma Presents Brain Delivery Studies at Alzheimer’s and Parkinson’s Diseases Conference 2026
By Karen Roman Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) said it presented new research findings at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders taking place March 17-21, 2026, in Copenhagen and online. The data displays efforts to advance Alzheimer’s treatment through three key areas which include developing enhanced brain delivery methods […]
Assessing Acumen Pharmaceuticals (ABOS) Valuation After New Phase 2 ALTITUDE-AD Trial Developments
Acumen Pharmaceuticals (ABOS) recently dosed the first participant in the open-label extension of its Phase 2 ALTITUDE-AD trial for sabirnetug, and also shared new Alzheimer’s research findings and upcoming recruitment plans. See our latest analysis for Acumen Pharmaceuticals. The recent clinical trial milestones appear to have coincided with strong momentum in the shares, with a 30.77% 1 day share price return, 46.24% 7 day share price return and a 70% 1 year total shareholder return, even...
Does Sabirnetug’s Phase 2 Extension and Insider Stock Sales Alter the Bull Case for ABOS?
Acumen Pharmaceuticals recently reported that it has dosed the first participant in the open-label extension of its Phase 2 ALTITUDE-AD trial for Alzheimer’s candidate sabirnetug, while its Chief Medical Officer and Chief Financial Officer sold shares to meet tax obligations from vested restricted stock units under pre-arranged plans. The combination of extending sabirnetug treatment for an additional 52 weeks and sharing fresh clinical findings and recruitment insights at an Alzheimer’s...
Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny Stocks
While mega-cap tech stocks with trillion-dollar valuations tend to dominate market headlines, they aren’t the only games in town. Smaller companies, especially those at the low end of the price spectrum, can offer meaningful upside. These are the so-called penny stocks – traditionally associated with shares trading for just pennies, but today defined more broadly as stocks priced below $5. At these low price levels, even small absolute price increases can translate into outsized percentage gains